In recent years, Scedosporium species have been more commonly recognized from severe, difficult-to-treat human infections, such as upper respiratory tract and pulmonary infections. To select an appropriate therapeutic approach for these infections is challenging, because of the commonly observed resistance of the causative agents to several antifungal drugs. Therefore, to find a novel strategy for the treatment of pulmonary Scedosporium infections the in vitro antifungal effect of a mucolytic agent, N-acetyl-Lcysteine and its in vitro combinations with conventional antifungals were investigated. Synergistic and indifferent interactions were registered in 23 and 13 cases, respectively. Antagonism was not revealed between the compounds.
Introduction
Members of the genus Scedosporium are known to cause localized infections in immunocompetent hosts or invasive mycoses in immunocompromised patients. Scedosporium apiospermum and related species may form fungus balls in patients with previous or underlying cavitary lung diseases (e.g., tuberculosis); they are frequent colonizers of the airways of cystic fibrosis patients and can cause Scedosporium pneumonia in otherwise healthy hosts. 1, 2 As their symptoms and clinical manifestations can be similar to aspergillosis, the real incidence and clinical importance of these pathogens may be underestimated. 2 In a recent survey involving fungal samples from 29 hospitals of Spain, Scedosporium species proved to be the second most frequently isolated filamentous fungi after Aspergilli. 3 Furthermore, their poor susceptibility to clinically used antifungals makes the Scedosporium infections difficult to treat. 1 Therefore, finding new agents with a better antifungal activity against these species is urgently needed.
N-acetyl-L-cysteine (NAC) has an excellent antioxidant activity and it is a commonly used mucolytic drug to treat acute infections of the respiratory tract. 4 The in vitro inhibitory effect of NAC has been previously proven against certain agriculturally and medically important filamentous fungal pathogens. 5, 6 In this study, we evaluated the in vitro antifungal effect of NAC against nine Scedosporium isolates and its combination with conventional antifungal agents.
Materials and methods
Pseudallescheria angusta (CBS 254.72 from sewage), Pseudallescheria ellipsoidea (CBS 301.79 from dung), Scedosporium boydii (previously known as Pseudallescheria boydii, CBS 120157, CBS 117410, CBS 117432 from human lung, soil, and sputum, respectively), and Scedosporium aurantiacum (CBS 136046, CBS 136047, CBS 136049, CBS 116910 from human lung, soil, soil and wound exudate, respectively) were involved in this study. Susceptibility tests were performed in accordance with the slightly modified instructions of the CLSI M38-A2 broth microdilution method, 7 in triplicates. Modifications related to stock solution and inoculum preparation were detailed previously. 8 The final drug concentrations in the tests ranged from 64 to 1024 μg ml −1 . In some cases, where the MICs of NAC (Sigma-Aldrich, USA) could not be determined in this concentration range, further higher concentrations (2048-8192 μg ml −1 ) were also tested. Drug interactions were investigated between NAC and four conventional antifungal agents (i.e., amphotericin B, AMB; caspofungin, CSP; terbinafine, TRB; and voriconazole, VRC) representing a polyene, an echionocandin, an allylamine, and an azole antimycotic, using the checkerboard microdilution method. 9 Serial twofold dilutions were prepared in a final concentration range of 64-4096 μg ml −1 for NAC, and 0.125-128 μg ml −1 for antifungal drugs. Fractional inhibitory concentration indexes (FICI) were calculated as described before.
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Results
Susceptibility of clinical Scedosporium spp. to NAC and its combination with antifungal drugs has not been investigated before. This paper provides the first MIC dataset about it. All the MIC values of NAC were in the range of 1024-8192 μg ml −1 ( (Table 1) . Antagonism was not detected between the investigated drugs. The idea behind combinational antifungal therapy is improving the antifungal effect and reducing the dosage of antifungals to avoid side-effects with the simultaneous application of two or more antifungal drugs. In our study, the MIC values of antifungals in combination with NAC could be decreased to their achievable plasma concentration in several cases. [11] [12] [13] [14] The MICs of NAC were also decreased in the combination tests; the lowest MIC value (64 μg ml −1 ) is still higher than its maximal plasma concentration, which is between 2.6-48.96 μg ml −1 depending on the dosage and the route of administration. [15] [16] [17] Apart from this, synergisms between antifungal agents and NAC suggest that it would be worthwhile to investigate the in vivo efficacy of these combinations, and to determine the clinical relevance of our results.
Conclusion
Although previous in vitro susceptibility data on the combinations of cysteine derivatives and conventional antifungal drugs are not available in the literature, another aspect of the co-administration was investigated and reported by Lee et al. 18 It was demonstrated that, in cancer or AIDS patients where itraconazole (ITC) metabolism is impaired due to the altered expression of cytochrome P450 (CYP), oral cysteine administration could restore the normal CYP and thus the ITC level, too. 18 This also supports that (beside the The MICs of AMB, CSP, TRB and VRC were determined previously by our research group. 8 at University Innsbruck on May 3, 2016 http://mmy.oxfordjournals.org/ Downloaded from direct inhibitory effect on fungi) NAC has other beneficial properties, which may improve the efficacy of a potential antifungal therapy and/or reduce the side effects caused by azoles. According to previous studies, NAC is able to increase the antioxidant capacity of the lung and enhance the antimicrobial activity of macrophages against Candida spp. 17, 19 Furthermore, in combination with antifungal therapy, the administration of NAC alleviated oxidative stress and lung injury associated with invasive pulmonary aspergillosis in a neutropenic mice model. 20 Our results together with the aforementioned considerations arise the need of further in vivo studies to clarify the efficacy and applicability of NAC in the treatment of pulmonary Scedosporium infections.
